CFP
LGND icon

Comprehensive Financial Planning’s Ligand Pharmaceuticals LGND Stock Holding History

Comprehensive Financial Planning’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2K Hold
66
– – 0.01% 247
2025
Q4 		$12.5K Buy
+66
New +$12.7K 0.01% 240

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Comprehensive Financial Planning's LGND Position: Q1 2026 in Review

Comprehensive Financial Planning held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 66 shares worth $13.2K. The position accounts for 0.01% of the portfolio, ranked #247.

Comprehensive Financial Planning first reported a position in LGND in Q4 2025 and has held it in 2 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Comprehensive Financial Planning held 66 shares of Ligand Pharmaceuticals worth $13.2K as of Q1 2026.
  • Comprehensive Financial Planning left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.01% of Comprehensive Financial Planning's portfolio in Q1 2026, its #247 holding.
  • Comprehensive Financial Planning first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Comprehensive Financial Planning's 13F filing for Q1 2026, filed 7 Apr 2026.